Core Insights - FitLife Brands, Inc. reported a 5% decrease in total revenue for Q2 2025, amounting to $16.1 million compared to $16.9 million in Q2 2024 [3][19] - The decline in online revenue was 7%, totaling $10.4 million, which represented 65% of total revenue for the quarter [3][19] - Gross margin decreased to 42.8% from 44.8% year-over-year, primarily due to increased merger and acquisition-related expenses [4][5][19] Financial Performance - Net income for Q2 2025 was $1.7 million, down from $2.6 million in Q2 2024, with basic and diluted earnings per share at $0.19 and $0.18, respectively [5][19] - Adjusted EBITDA decreased by 13% to $3.3 million compared to the same period in 2024, with trailing twelve months adjusted EBITDA at $13.4 million [6][19] - The company ended the quarter with $10.9 million in term loans and $6.6 million in cash, resulting in total net debt of $4.3 million, approximately 0.3x adjusted EBITDA [7][19] Brand Performance - Legacy FitLife revenue increased by 7% year-over-year, driven by a 17% increase in online revenue and a 1% increase in wholesale revenue [11][12] - MRC revenue decreased by 16% compared to Q2 2024, with significant declines in the Dr. Tobias brand and skin care brands due to reduced traffic and tariffs [13][14][15] - MusclePharm revenue decreased by 4%, with wholesale revenue down 6% and online revenue down 3%, although the company is investing in advertising to drive growth [17][18][24] Acquisition Activity - The company completed the acquisition of Irwin Naturals for $42.5 million on August 8, 2025, funded primarily through a new term loan and available cash [20][26] - Irwin Naturals generated approximately $60 million in revenue with a gross margin of about 35% for the trailing twelve months as of June 30, 2025 [25][26] - Management expects to achieve cost savings and improved gross margins as they integrate Irwin Naturals into their operations [26][27]

Vancouver, British Columbia – August 13, 2025 – TheNewswire - Pangea Natural Foods Inc. (CSE: PNGA) (OTC: PNGAF) ("Pangea" or the "Company") is pleased to announce that its subsidiary Amino Innovations successfully showcased its portfolio of science-backed, non-injectable peptide products at TheFitExpo in Anaheim, California. The event, held on August 2nd-3rd at the Anaheim Convention Center, attracted more than 20,000 attendees, including fitness enthusiasts, trainers, wellness professionals, and influence ...

Forward-Looking Statements Statements in this press release that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve substantial risks, uncertainties and assumptions, including statements related to the Company and Irwin and our acquisition of Irwin's assets that could cause actual results to differ materially from those expressed ...

Financial Data and Key Metrics Changes - Net sales for Q2 2025 were $1.3 billion, down 1.7% compared to 2024, but flat on a constant currency basis [7][24] - Adjusted EBITDA was $174 million, exceeding guidance, with an adjusted EBITDA margin of 13.8%, down 30 basis points year over year due to unfavorable currency impacts [24][27] - The company paid down $55 million in debt during the quarter, maintaining a total leverage ratio of slightly under three times as of June 30 [27][28] Business Line Data and Key Metrics Changes - Product innovation included the launch of Multi Burn, a non-pharmaceutical weight loss supplement, and the introduction of a healthy lifespan product [6][19] - Distributor growth initiatives led to strong engagement, with nearly 38,000 attendees at training events globally [9][10] - New distributor growth was flat year over year, but four out of five regions saw increases, with Latin America leading at 16% growth [9] Market Data and Key Metrics Changes - In North America, net sales were down 4%, primarily due to a 6% decline in year-over-year volumes, but July marked the first month of year-over-year volume growth since April 2021 [33][8] - Latin America reported a strong performance with constant currency net sales up 9%, despite reported net sales being down 1% [31] - EMEA net sales were flat on a reported basis, while Asia Pacific saw a 2% decline in reported net sales [32] Company Strategy and Development Direction - The company aims to transform into a data-driven wellness platform, integrating technology and personalized solutions to meet evolving consumer needs [4][5] - The acquisition of Link Biosciences is expected to enhance personalized supplement formulations, providing a competitive advantage [21] - The company is focused on expanding its product offerings and enhancing distributor engagement through digital tools and AI [17][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's transformation and noted signs of accelerating momentum in sales [5][8] - The outlook for Q3 includes projected net sales growth of 0.5% to 4.5% year over year, with adjusted EBITDA expected to be between $150 million and $160 million [38][39] - The company has raised and narrowed its full-year net sales guidance range to down 1% to up 3% year over year [39][40] Other Important Information - The company is integrating the Protocol app, which aims to enhance distributor-customer connections and provide personalized health insights [11][12] - The launch of the Protocol app is expected to create new monetization opportunities and attract a new customer segment [48][63] - The company plans to expand the Protocol platform globally, with regulatory assessments underway for key markets [68] Q&A Session Summary Question: What are the monetization strategies for the Protocol app? - Management indicated that the app will serve as a tool for distributors to enhance customer engagement and will have options for both product and app subscriptions [48][63] Question: How does the company view pricing in relation to competitors? - The company plans to take pricing in line with market conditions and has not seen significant pressure from competitors [56][58] Question: What are the plans for high-cost debt management? - The company is considering refinancing options for high-cost debt as market conditions improve [69]

During the first half of 2025, Irwin generated revenue of $33.1 million and adjusted EBITDA of $3.9 million. Consistent with seasonality patterns in the nutritional supplement industry, FitLife expects the second half of the year to be somewhat softer than the first half of the year. OMAHA, NE, Aug. 05, 2025 (GLOBE NEWSWIRE) -- FitLife Brands, Inc. ("FitLife," or the "Company") (Nasdaq: FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, announced that it has enter ...

Core Viewpoint - FitLife Brands, Inc. plans to report its financial performance for Q2 of fiscal 2025 on August 14, 2025 [1] Group 1: Financial Reporting - The financial performance report for Q2 fiscal 2025 will be released on August 14, 2025 [1] - An investor conference call is scheduled for August 14, 2025, at 4:30 pm ET [2] - Participants can join the call using specific dial-in numbers and a conference identification code [2] Group 2: Company Overview - FitLife Brands is a developer and marketer of nutritional supplements and wellness products [3] - The company offers over 250 different products, primarily marketed online and through GNC® franchise locations [3] - FitLife Brands is headquartered in Omaha, Nebraska [3]

Financial Data and Key Metrics Changes - Revenue for Q2 2025 was $115 million, a 4% increase year-over-year or 2% in constant currency [6][14] - Adjusted EBITDA for Q2 was $11 million, an 8% increase from $10 million in the prior year [6][22] - GAAP net income attributable to common shareholders was $5.3 million or $0.28 per diluted share, compared to $1.3 million or $0.07 per diluted share in the prior year [22] - Gross margin increased by 36 basis points to 71.7% compared to the previous year [20] Business Line Data and Key Metrics Changes - North America sales grew 4%, with digital sales increasing by 34% [10][15] - Asia Pacific sales increased by 5%, driven by a 27% increase in Japan [7][16] - Europe sales were up 1% but down 2% in constant currency, with Central Europe showing strong growth of 15% [12][19] Market Data and Key Metrics Changes - In North America, the digital business saw significant growth, contributing to overall sales growth [10][15] - Japan's sales growth was notable, with a consistent 20%+ growth for four consecutive quarters [16] - Taiwan and South Korea faced challenges due to a slowing macroeconomic environment, impacting sales growth [9][18] Company Strategy and Development Direction - The company is focused on long-term sustainable growth through strong consumer engagement and execution of sales and marketing strategies [6][7] - The strategy includes sharpening digital execution, stabilizing the core business in North America, and driving growth in key international markets [12][13] - The company is increasing its full-year guidance based on strong first-half performance and positive momentum [13][24] Management's Comments on Operating Environment and Future Outlook - Management acknowledged ongoing macroeconomic uncertainties but expressed confidence in the company's fundamentals and growth strategy [6][7] - The outlook for the second half of the year includes expectations for continued growth in North America and stabilization in Asia Pacific [55][56] - Management is optimistic about future growth prospects, particularly in digital sales and new product innovations [25][62] Other Important Information - The company repurchased 1.1 million shares for approximately $12.3 million during the first half of 2025 [23] - Inventory increased to $69.3 million as the company prepared for potential supply chain disruptions [23] Q&A Session Summary Question: Clarification on EBITDA guidance range - Management indicated that the range reflects confidence in North America and the digital business, with performance dependent on continued acceleration [27][28] Question: Insights on SG&A expenses and digital investment - Management confirmed increased digital investment in Q2, with plans to continue funding if strong returns are observed [32][34] Question: Impact of new product innovations - New products are expected to provide consumer energy and acquisition, with cumulative effects anticipated over time [61][62] Question: Capacity and potential partnerships - The company is exploring opportunities to leverage increased manufacturing capacity through organic growth and potential partnerships [40][41] Question: Growth expectations in North America and Asia - Continued acceleration in North America is expected, while Asia Pacific will see growth but at lower rates compared to previous quarters [51][55]

LEHI, Utah, July 31, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (Nasdaq: NATR) ("Nature's Sunshine"), a leading manufacturer of high-quality herbal and nutritional supplements, reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Summary vs. Same Year-Ago Quarter Volume incentives as a percentage of net sales were 29.9% compared to 31.4% in the year-ago quarter. The decrease was primarily due to timing of promotional incentives and changes in pr ...

全粉色沉浸式展位，传递 "母婴友好" 初心 花颜 28—— 日 "养" 根基，状态吃饱不掉线 汇集 28 种自然养分，花颜 28 为女性提供全面支持。从日常补充，到孕期营养储备及产后修复，通过平 衡代谢需求，以细密滋养守护生命绽放，成为母婴健康路上的贴心伙伴。 metoday 展位以全粉色为主视觉，用柔和灯光与通透陈设构建起温暖治愈的沉浸式空间。不同于传统母 婴场景的刻意呈现，这里通过色彩与氛围的细腻表达，将 "母婴友好" 的理念融入每一处细节。温柔的 粉色基调呼应着女性对 "温和、安心" 的需求，通透的布局与舒适的动线让参观者在放松的氛围中感受 品牌温度。以自然舒展的姿态传递着品牌对母婴群体的重视，让 "自内而外的滋养" 从产品延伸至体 验，用氛围诉说这一女性需求的深层理解。 三大主推品亮相，构建营养解决方案 补铁爆珠 ——"红" 粉佳人，面若桃花不用妆 针对全年龄段女性气血需求，metoday 补铁爆珠以独特配方激活血红蛋白活力，让红润气色自然晕染。 无论是孕期妈妈还是职场女性，都能通过温和滋养重获元气，从容应对生活挑战。 虾青素 —— 日透 "光" 感，暗黄退散 聚焦内服防晒新趋势，虾青素以高活性抗氧化 ...

Core Viewpoint - USANA Health Sciences (USNA) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on an upward trend in earnings estimates, which significantly influences stock prices [1][2]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements. Institutional investors utilize these estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [3][4]. - Rising earnings estimates for USANA Health suggest an improvement in the company's underlying business, which could lead to an increase in stock price as investors respond positively to this trend [4]. Zacks Rank System - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [6]. - The Zacks rating system maintains a balanced distribution of "buy" and "sell" ratings across its universe of over 4,000 stocks, ensuring that only the top 20% receive a "Strong Buy" or "Buy" rating [8][9]. Earnings Estimate Revisions for USANA Health - For the fiscal year ending December 2025, USANA Health is expected to earn $2.62 per share, which remains unchanged from the previous year. However, the Zacks Consensus Estimate has increased by 0.4% over the past three months, indicating a positive trend in earnings expectations [7].